Varian Medical Systems Particle Therapy GmbH & Co. KG

Varian Medical Systems Particle Therapy GmbH & Co. KG specializes in proton therapy systems, which are advanced radiation treatment devices. These systems are designed to deliver precise proton beams to tumors, reducing exposure to healthy tissue compared to traditional radiation therapy. The company offers both fixed beam and rotating gantry configurations, such as the ProBeam Proton Therapy System, tailored for targeted cancer treatment.

The company is based in the United States, operating under a US-based entity. While the company itself is not approved or cleared, its devices—such as the ProBeam systems—are classified as Class II under regulatory frameworks, indicating a moderate level of risk that requires special controls to ensure safety and effectiveness. This classification applies to individual devices, not the company as a whole.

Yes, Varian’s proton therapy systems are listed in the FDA’s Unique Device Identifier (UDI) database. This listing helps ensure traceability and transparency in the medical device supply chain, allowing healthcare providers, regulators, and patients to verify the identity and regulatory status of the devices. Being listed in the UDI database is a key requirement for Class II devices in the US, supporting compliance and accountability.

Varian’s proton therapy systems are classified as Class II devices. This classification means they pose a moderate risk and require special controls beyond general controls (like good manufacturing practices) to ensure their safety and performance. Class II devices typically undergo a premarket notification (510(k)) process to demonstrate substantial equivalence to a legally marketed predicate device, ensuring they meet regulatory requirements before entering the market.